Liguang Lou

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 13

Top Topics

Endoplasmic Reticulum Stress

Tyrosine Kinase

Cell Cycle Arrest

Positive Breast Cancer

Top Venues

Journal of cellular and molecular medicine

Thoracic cancer

British journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Wei Zhou, Peng Fang, Dongan Yu, Hongyuan Ren, Meng You, Long Yin, Fei Mei, Huikai Zhu, Zhenzhen Wang, Hui Xu, Yuxia Cao, Xiaowei Sun, Xiaohong Xu, Jianjun Bi, Jin Wang, Lanping Ma, Xin Wang, Lin Chen, Yongliang Zhang, Xiaowei Cen, Xi Zhu, Liguang Lou, Datao Liu, Xiaoding Tan, Jinliang Yang, Tao Meng, Jingkang Shen
Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers. Molecular cancer therapeutics (2023)
Mi Zhang, Haitian Quan, Li Fu, Yun Li, Haoyu Fu, Liguang Lou
Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells. Thoracic cancer 12 (8) (2021)
Lu Chen, Haitian Quan, Zhongliang Xu, Hao Wang, Yuanzhi Xia, Liguang Lou, Weibo Yang
A modular biomimetic strategy for the synthesis of macrolide P-glycoprotein inhibitors via Rh-catalyzed C-H activation. Nature communications 11 (1) (2020)
Lei Wang, Quanren Wang, Piaopiao Xu, Li Fu, Yun Li, Haoyu Fu, Haitian Quan, Liguang Lou
YES1 amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer. British journal of cancer 123 (6) (2020)
Fei Long, Ye He, Haoyu Fu, Yun Li, Xubin Bao, Quanren Wang, Yigang Wang, Chengying Xie, Liguang Lou
Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models. Cancer science 110 (4) (2019)
Mengya Tong, Mingzhao Gao, Yongping Xu, Li Fu, Yun Li, Xubin Bao, Haoyu Fu, Haitian Quan, Liguang Lou
SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met. Cancer science 110 (11) (2019)
Mingzhao Gao, Hongmei Zhu, Li Fu, Yun Li, Xubin Bao, Haoyu Fu, Haitian Quan, Lei Wang, Liguang Lou
Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants. Cancer science 110 (10) (2019)
Lei Wang, Changyong Yang, Chengying Xie, Jiahua Jiang, Mingzhao Gao, Li Fu, Yun Li, Xubin Bao, Haoyu Fu, Liguang Lou
Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials. Cancer science 110 (3) (2019)
Lei Wang, Quanren Wang, Mingzhao Gao, Li Fu, Yun Li, Haitian Quan, Liguang Lou
STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer. Cancer science 109 (10) (2018)
Chengying Xie, Xiaozhe Wan, Haitian Quan, Mingyue Zheng, Li Fu, Yun Li, Liguang Lou
Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer science 109 (4) (2018)
Chengying Xie, Huajun Zhao, Xubin Bao, Haoyu Fu, Liguang Lou
Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist. Journal of cellular and molecular medicine 22 (11) (2018)
Hongbin Wang, Wenqian Wang, Yongping Xu, Yong Yang, Xiaoyan Chen, Haitian Quan, Liguang Lou
Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells. Cancer science 108 (7) (2017)
Chengying Xie, Ye He, Mingyue Zhen, Yulan Wang, Yongping Xu, Liguang Lou
Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia. Cancer science 108 (7) (2017)